Back to top
more

National Vision (EYE)

(Real Time Quote from BATS)

$10.28 USD

10.28
406,316

+0.30 (3.01%)

Updated Sep 11, 2024 01:10 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value C Growth F Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 34% (84 out of 250)

Industry: Medical - Products

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

National Vision (EYE) Q4 Earnings and Revenues Top Estimates

by Zacks Equity Research

National Vision (EYE) delivered earnings and revenue surprises of 246.15% and 5.86%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

National Vision (EYE) Earnings Expected to Grow: What to Know Ahead of Q4 Release

by Zacks Equity Research

National Vision (EYE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

National Vision (EYE) Rides on Comps Growth Amid COVID-19 Woes

by Zacks Equity Research

National Vision's (EYE) Eyeglass pumps sales are robust driven by increases in both customer transactions and average ticket.

Why Is National Vision (EYE) Down 5.4% Since Last Earnings Report?

by Zacks Equity Research

National Vision (EYE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

National Vision (EYE) Q3 Earnings Top Estimates, Margins Up

by Zacks Equity Research

National Vision (EYE) witnesses comparable growth on increased customer transaction in Q3.

National Vision (EYE) Q3 Earnings Surpass Estimates

by Zacks Equity Research

National Vision (EYE) delivered earnings and revenue surprises of 107.69% and -1.45%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

National Vision (EYE) to Report Q3 Earnings: What's in Store?

by Zacks Equity Research

National Vision's (EYE) contact lens revenue growth is expected to have remained impressive in Q3 on lesser impact of store closures.

National Vision (EYE) Reports Next Week: Wall Street Expects Earnings Growth

by Zacks Equity Research

National Vision (EYE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

National Vision Banks on Contact Lens Sales Amid Coronavirus Woes

by Zacks Equity Research

National Vision (EYE) sales bear the impact of unfavorable timing of unearned revenues.

Why Is National Vision (EYE) Up 18.4% Since Last Earnings Report?

by Zacks Equity Research

National Vision (EYE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Surging Earnings Estimates Signal Upside for National Vision (EYE) Stock

by Zacks Equity Research

National Vision (EYE) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.

National Vision (EYE) Stock on the Rise Since Q2 Earnings Beat

by Zacks Equity Research

Investors seem to be impressed with National Vision's (EYE) better-than-expected second-quarter 2020 results despite the coronavirus-led economic crisis.

National Vision (EYE) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

National Vision (EYE) delivered earnings and revenue surprises of 28.07% and 6.91%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

Should You Buy National Vision (EYE) Ahead of Earnings?

by Zacks Equity Research

National Vision (EYE) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Analysts Estimate National Vision (EYE) to Report a Decline in Earnings: What to Look Out for

by Zacks Equity Research

National Vision (EYE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

National Vision (EYE) Q1 Earnings Top Estimates, Margin Falls

by Zacks Equity Research

National Vision's (EYE) first-quarter 2020 results were better than expected despite the coronavirus-led economic crisis.

Here's Why You Should Add Tandem Diabetes to Your Portfolio

by Zacks Equity Research

Investors continue to be optimistic about Tandem Diabetes (TNDM) on its strength in the diabetes business and receipt of regulatory approvals.

    Walgreens' Retail Pharmacy Grows Amid Coronavirus Crisis

    by Zacks Equity Research

    Walgreens (WBA) registers growing demand for Retail Pharmacy & Pharmaceutical Wholesale products in Q2.

    Abbott Launches Antibody Test to Detect Coronavirus Infection

    by Zacks Equity Research

    Abbott (ABT) launches a lab-based serology blood test to detect the presence of antibodies post the coronavirus infection.

    QIAGEN Launches Assay for Cancer Patients Following FDA's Nod

    by Zacks Equity Research

    QIAGEN (QGEN) paves the way for metastatic CRC treatment in adults with the launch of an FDA-approved companion diagnostic test kit.

    NuVasive (NUVA) Posts Q1 Preliminary Results, Withdraws View

    by Zacks Equity Research

    A decline in elective surgical procedures due to coronavirus outbreak weighs on NuVasive's (NUVA) preliminary revenue results for first-quarter 2020.

    QIAGEN (QGEN) Reports Preliminary Revenue Results for Q1

    by Zacks Equity Research

    Investors remain optimistic with QIAGEN's (QGEN) first-quarter 2020 preliminary revenue results, which is likely to benefit from increased testing demand for coronavirus infection.

    Illumina (ILMN) Posts Q1 Preliminary Results, Withdraws View

    by Zacks Equity Research

    Investors remain optimistic on Illumina's (ILMN) strong preliminary revenue results for first-quarter 2020.

    Here's Why You Should Add ResMed (RMD) in Your Portfolio

    by Zacks Equity Research

    Investors continue to be optimistic about ResMed (RMD) on its focus on digital health technology and combatting the coronavirus outbreak.

    Bio-Rad Rides on International Expansion Amid Cost Concerns

    by Zacks Equity Research

    Each of Bio-Rad's (BIO) key segments registers solid growth across three major geographies of America, Europe and Asia.